Verition Fund Management
PDSB icon

Verition Fund Management’s PDS Biotechnology PDSB Stock Holding History

Verition Fund Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,774
Closed -$130K – 2605
2023
Q3 		$130K Sell
25,774
-5,126
-17% -$28.1K ﹤0.01% 2082
2023
Q2 		$155K Buy
30,900
+7,869
+34% +$51.5K ﹤0.01% 1911
2023
Q1 		$142K Buy
+23,031
New +$188K ﹤0.01% 1855

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management's PDSB Position: Q4 2023 in Review

Verition Fund Management sold out of PDS Biotechnology (PDSB) in Q4 2023, closing a stake of 25,774 shares — an estimated $130K sold.

Verition Fund Management first reported a position in PDSB in Q1 2023 and held it in 3 quarters. The position peaked at $155K in Q2 2023. 77 funds tracked by Wall St. Rank hold PDSB as of Q4 2023.

  • Verition Fund Management reported no remaining PDS Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 25,774 PDS Biotechnology shares in Q4 2023, an estimated $130K.
  • Verition Fund Management first reported a position in PDS Biotechnology in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's PDS Biotechnology position peaked at $155K in Q2 2023.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.